Analyzing large Alzheimer's disease cognitive datasets: Considerations and challenges
- PMID: 33313379
- PMCID: PMC7720865
- DOI: 10.1002/dad2.12135
Analyzing large Alzheimer's disease cognitive datasets: Considerations and challenges
Abstract
Recent data-sharing initiatives of clinical and preclinical Alzheimer's disease (AD) have led to a growing number of non-clinical researchers analyzing these datasets using modern data-driven computational methods. Cognitive tests are key components of such datasets, representing the principal clinical tool to establish phenotypes and monitor symptomatic progression. Despite the potential of computational analyses in complementing the clinical understanding of AD, the characteristics and multifactorial nature of cognitive tests are often unfamiliar to computational researchers and other non-specialist audiences. This perspective paper outlines core features, idiosyncrasies, and applications of cognitive test data. We report tests commonly featured in data-sharing initiatives, highlight key considerations in their selection and analysis, and provide suggestions to avoid risks of misinterpretation. Ultimately, the greater transparency of cognitive measures will maximize insights offered in AD, particularly regarding understanding the extent and basis of AD phenotypic heterogeneity.
Keywords: Alzheimer's disease; cognition; cognitive tests; composite scores; data‐driven computational models; data‐sharing initiatives; mild cognitive impairment; predictive models.
© 2020 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.
Conflict of interest statement
The authors declare that they have no conflicts of interest.
Figures
Similar articles
-
Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.Alzheimers Dement. 2019 Jan;15(1):106-152. doi: 10.1016/j.jalz.2018.08.005. Epub 2018 Oct 13. Alzheimers Dement. 2019. PMID: 30321505 Review.
-
The Alzheimer's Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer's disease.Alzheimers Res Ther. 2020 May 27;12(1):66. doi: 10.1186/s13195-020-00633-2. Alzheimers Res Ther. 2020. PMID: 32460855 Free PMC article.
-
Neuroimaging and analytical methods for studying the pathways from mild cognitive impairment to Alzheimer's disease: protocol for a rapid systematic review.Syst Rev. 2020 Apr 2;9(1):71. doi: 10.1186/s13643-020-01332-7. Syst Rev. 2020. PMID: 32241302 Free PMC article.
-
Heterogeneity and Factorial Structure in Alzheimer's Disease: A Cognitive Perspective.J Alzheimers Dis. 2021;83(3):1341-1351. doi: 10.3233/JAD-210719. J Alzheimers Dis. 2021. PMID: 34420975
-
Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer's disease.Alzheimers Res Ther. 2022 Apr 19;14(1):54. doi: 10.1186/s13195-022-00984-y. Alzheimers Res Ther. 2022. PMID: 35440022 Free PMC article. Review.
Cited by
-
A guide for researchers seeking training in retrospective data harmonization for population neuroscience studies of Alzheimer's disease and related dementias.Front Neuroimaging. 2022;1:978350. doi: 10.3389/fnimg.2022.978350. Epub 2022 Sep 26. Front Neuroimaging. 2022. PMID: 37464990 Free PMC article.
-
Chronic neuropsychiatric sequelae of SARS-CoV-2: Protocol and methods from the Alzheimer's Association Global Consortium.Alzheimers Dement (N Y). 2022 Sep 22;8(1):e12348. doi: 10.1002/trc2.12348. eCollection 2022. Alzheimers Dement (N Y). 2022. PMID: 36185993 Free PMC article.
-
Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations.Transl Neurodegener. 2022 May 2;11(1):24. doi: 10.1186/s40035-022-00299-w. Transl Neurodegener. 2022. PMID: 35491418 Free PMC article. Review.
References
Grants and funding
LinkOut - more resources
Full Text Sources